Journal of Clinical Oncology, Vol 12, 1497-1515, Copyright © 1994 by American Society of Clinical Oncology
Antibodies as cytotoxic therapy
RO Dillman
Hoag Cancer Center, Newport Beach, CA 92663.
PURPOSE: This review was conducted to characterize the results of trials of
unconjugated monoclonal antibodies in the treatment of cancer. This survey
does not cover antibodies conjugated to drugs, isotopes, or toxins.
METHODS: An English-language literature search was used to identify reports
of trials of unconjugated monoclonal antibodies in patients with cancer.
RESULTS: Most trials have been pilot or phase I to II in nature. The most
encouraging results have been described for various antibodies directed
against lymphoma, and for certain monoclonal antibodies that bind to
glycolipid antigens on melanoma, sarcoma, and neuroblastoma. Toxicity has
not been a major problem with these reagents, but human antimouse
antibodies have limited the potential application of murine reagents.
CONCLUSION: At present, there are no unconjugated monoclonal antibodies
that have proven therapeutic benefit in hematologic malignancies or solid
tumors. The most active areas of current interest relate to antibodies to
various growth factor receptors and the testing of humanized antibodies.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R. K. Oldham and R. O. Dillman
Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
J. Clin. Oncol.,
April 10, 2008;
26(11):
1774 - 1777.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, X.-M. Xu, C. B. Underhill, S. Yang, L. Wang, Y. Chen, S. Hong, K. Creswell, and L. Zhang
Tachyplesin Activates the Classic Complement Pathway to Kill Tumor Cells
Cancer Res.,
June 1, 2005;
65(11):
4614 - 4622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Grube, K. Rezvani, A. Wiestner, H. Fujiwara, G. Sconocchia, J. J. Melenhorst, N. Hensel, G. E. Marti, L. W. Kwak, W. Wilson, et al.
Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies
Clin. Cancer Res.,
February 1, 2004;
10(3):
1047 - 1056.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. O. Dillman
Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma
J. Clin. Oncol.,
August 15, 2002;
20(16):
3545 - 3557.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. van Spriel, J. H. W. Leusen, M. van Egmond, H. B. P. M. Dijkman, K. J. M. Assmann, T. N. Mayadas, and J. G. J. van de Winkel
Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation
Blood,
April 15, 2001;
97(8):
2478 - 2486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kee Shin, E. Young Choi, S. Hyung Kim, J. Chung, D. Hyun Chung, W. Seo Park, K. Cheon Jung, H. Sik Kim, S. Park, H. Jin Kim, et al.
Expression of Leukemia-Associated Antigen, JL1, in Bone Marrow and Thymus
Am. J. Pathol.,
April 1, 2001;
158(4):
1473 - 1480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-A. Ghetie, H. Bright, and E. S. Vitetta
Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
Blood,
March 1, 2001;
97(5):
1392 - 1398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hosch, J. Kraus, P. Scheunemann, J. R. Izbicki, C. Schneider, U. Schumacher, K. Witter, M. R. Speicher, and K. Pantel
Malignant Potential and Cytogenetic Characteristics of Occult Disseminated Tumor Cells in Esophageal Cancer
Cancer Res.,
December 1, 2000;
60(24):
6836 - 6840.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. M. Vose, R. L. Wahl, M. Saleh, A. Z. Rohatiner, S. J. Knox, J. A. Radford, A. D. Zelenetz, G. F. Tidmarsh, R. J. Stagg, and M. S. Kaminski
Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
J. Clin. Oncol.,
March 13, 2000;
18(6):
1316 - 1323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Braun, F. Hepp, C. R. M. Kentenich, W. Janni, K. Pantel, G. Riethmuller, F. Willgeroth, and H. L. Sommer
Monoclonal Antibody Therapy with Edrecolomab in Breast Cancer Patients: Monitoring of Elimination of Disseminated Cytokeratin-positive Tumor Cells in Bone Marrow
Clin. Cancer Res.,
December 1, 1999;
5(12):
3999 - 4004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Kricka
Human Anti-Animal Antibody Interferences in Immunological Assays
Clin. Chem.,
July 1, 1999;
45(7):
942 - 956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Strau{beta}, B. Guckel, D. Wallwiener, and G. Moldenhauer
Without Prior Stimulation, Tumor-associated Lymphocytes from Malignant Effusions Lyse Autologous Tumor Cells in the Presence of Bispecific Antibody HEA125xOKT3
Clin. Cancer Res.,
January 1, 1999;
5(1):
171 - 180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Tutt, R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. E. Parkhouse, G. G. B. Klaus, and M. J. Glennie
Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors
J. Immunol.,
September 15, 1998;
161(6):
3176 - 3185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. T. Blok, M. R. Daha, O. Tijsma, C. L. Harris, B. P. Morgan, G. J. Fleuren, and A. Gorter
A Bispecific Monoclonal Antibody Directed Against Both the Membrane-Bound Complement Regulator CD55 and the Renal Tumor-Associated Antigen G250 Enhances C3 Deposition and Tumor Cell Lysis by Complement
J. Immunol.,
April 1, 1998;
160(7):
3437 - 3443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Valerius, B. Stockmeyer, A. B. van Spriel, R. F. Graziano, I. E. van den Herik-Oudijk, R. Repp, Y. M. Deo, J. Lund, J. R. Kalden, M. Gramatzki, et al.
Fcalpha RI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy
Blood,
December 1, 1997;
90(11):
4485 - 4492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-A. Ghetie, E. M. Podar, A. Ilgen, B. E. Gordon, J. W. Uhr, and E. S. Vitetta
Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
PNAS,
July 8, 1997;
94(14):
7509 - 7514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Hornick, L. A. Khawli, P. Hu, M. Lynch, P. M. Anderson, and A. L. Epstein
Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 With Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions While Retaining Tumor Targeting Properties
Blood,
June 15, 1997;
89(12):
4437 - 4447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hartmann, C. Renner, W. Jung, C. Deisting, M. Juwana, B. Eichentopf, M. Kloft, and M. Pfreundschuh
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
Blood,
March 15, 1997;
89(6):
2042 - 2047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gidlof, M. Dohlsten, P. Lando, T. Kalland, C. Sundstrom, and T. H. Totterman
A Superantigen-Antibody Fusion Protein for T-Cell Immunotherapy of Human B-Lineage Malignancies
Blood,
March 15, 1997;
89(6):
2089 - 2097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
